Efgartigimod alfa targets FcRn across three neuroimmune conditions
New drug shows promise for rare autoimmune nerve conditions
Efgartigimod alfa blocks FcRn to lower circulating IgG. It is approved for myasthenia gravis and CIDP, but not Guillain-Barré syndrome.
A new medication targets the immune system to treat rare nerve conditions, though it is not yet approved for all patients.
PLEX and corticosteroids show highest clinical response rates in chronic inflammatory demyelinating polyradiculoneuropathy
New FcRn Inhibitors Show Promise for Chronic Inflammatory Neuropathy
This systematic review and network meta-analysis of 2,184 patients evaluated various treatments for chronic inflammatory demyelinating polyr…
Newer treatments like efgartigimod alfa may offer significant clinical responses and improved grip strength for patients with chronic inflam…